Protein aggregation has been associated with a wide range of highly debilitating and increasingly prevalent human diseases, ranging from neurodegenerative disorders to nonneuropathic amyloidoises. One of the most widespread neurodegenerative diseases is Alzheimer's disease (AD), which is the leading cause of dementia, affecting millions of people worldwide and imposing an enormous economic burden in terms of health and hospice care. AD disrupts the communication between nerve cells in the brain, which becomes apparent as a gradual loss of memory from the age of 65 years and older in the majority of AD cases. As AD pathology spreads throughout the brain causing cell death and brain atrophy, AD patients experience a decline in thinking skills, behavioural problems, and eventually lose their personal identity and ability to communicate, depending entirely on others for care.
More than a century has passed since Alois Alzheimer first described the disease now named after him and significant progress has been made to understand the cellular and molecular events that are responsible for the progressive dysfunction and death of nerve cells. Despite extensive testing of numerous drug compounds in clinical trials, there is unfortunately still no means of halting or reverting AD progression, and current treatment is limited to the alleviation of disease symptoms. As the number of AD cases has been predicted to nearly triple by 2050 in the ageing global population, there is a growing and urgent need to find an effective AD therapy.
Substantial evidence points to the amyloid-beta (Aβ) peptide as a major causative factor in AD. The Aβ peptide is cleaved from the transmembrane amyloid precursor protein by β-and γ-secretase. This apparently harmless intrinsically disordered monomeric peptide converts into higher ordered and toxic aggregates, and eventually into amyloid fibrils that deposit into extracellular plaques in the brain. Aβ aggregation initiates a cascade of molecular events culminating in widespread neurodegeneration. The amyloid cascade hypothesis suggests that synapto-and neurotoxicity in AD is mediated by soluble Aβ oligomers. However, it has proven difficult to study these aggregates in vivo with the currently available technology, due to the dynamic nature of the Aβ peptide. The dynamics, stability, and transient lifetime of potentially toxic species hamper the possibility to precisely pinpoint the structural aspects of toxic Aβ aggregates. Moreover, the dynamic behaviour of aggregation intermediates may actually be an important driver of Aβ toxicity as the ongoing aggregation process has also been suggested to be a culprit for toxicity.
We postulate that the dynamic nature of the Aβ peptide is a complicating factor that contributes to AD pathogenesis and should be taken into account in therapeutic AD strategies. The research presented in this doctoral thesis aims to provide more insight into Aβ dynamics.
The influence of genetic variability and external regulating factors on Aβ dynamics, in particular on the aggregation and structural properties of Aβ, is investigated in vitro using a biophysical approach complemented with cell culture studies.
The first part of this thesis extensively reviews what has been reported in the literature on Aβ dynamics, including intra-and intermolecular dynamics (Chapter 1). Intramolecular Aβ dynamics encompass the intrinsically disordered nature of Aβ and the inherent flexibility of the polypeptide backbone present in every Aβ aggregation state. Intermolecular Aβ dynamics are illustrated by (i) the highly transient and interconverting forms of Aβ, and by (ii) the variability and interactions within the pool of different Aβ peptide variants in the brain. Furthermore, the dynamic nature of Aβ allows it to interact with many other molecules that can modulate Aβ properties. Variability in terms of space (different brain compartments and patient-to-patient differences) and time (ageing, lifestyle, and circadian rhythm) imposes an additional facet to the complex and dynamic "Aβ network".
The second part of this thesis focuses on certain aspects of Aβ dynamics and discusses their potential impact on AD pathology.
First, the heterogeneity within the in vivo Aβ peptide pool was investigated (Chapter 2). We monitored the in vitro aggregation of (i) N-and C-terminal varying Aβ peptides, (ii) Aβ mutants associated with the hereditary familial type of AD (FAD), and (iii) biotinylated Aβ, as this modified variant is often used in in vitro studies. We demonstrate that minor sequential variations in the Aβ peptide sequence have profound effects on Aβ aggregation. These findings are of interest in light of secretase activity-modifying AD therapeutic strategies that aim to lower Aβ production or alter the ratios between the generated Aβ peptide variants.
In chapter 3, we present the aggregation, structural, and inflammatory properties of the Italian E22K Aβ mutant that is causative of early-onset FAD associated with cerebral amyloid angiopathy (CAA). Our findings show that the Italian Aβ mutant forms fibrils containing an antiparallel β-sheet structure, in comparison to wild type fibrils that consist of parallel β-sheets, as do most amyloid fibrils reported in the literature. We suggest that this unique antiparallel structural signature might explain the clinical differences between the Italian mutant and wild type Aβ. We suggest that it predisposes the mutant to deposit mainly in the walls of the brain blood vessels causing CAA, rather than accumulating in amyloid plaques in the brain parenchyma.
Next, two interaction partners of Aβ were the subject of study: (i) Apolipoprotein E (ApoE) that exists as three isoforms (ApoE2, ApoE3, and ApoE4) with ApoE4 being an important risk factor for late-onset AD, and (ii) insulin-degrading enzyme (IDE), one of the proteases in the brain that is capable of cleaving Aβ. First, we show that lipid-free ApoE in solution aggregates in vitro, in particular ApoE4, whereas lipidation of ApoE impedes this behaviour (Chapter 4). Although ApoE is mainly lipidated in the brain, lipid-poor ApoE reservoirs exist that could lead to the formation of ApoE aggregates. As ApoE4 aggregates have been reported to be neurotoxic, this might explain the higher AD risk associated with ApoE4, in comparison with other ApoE isoforms. Second, we provide evidence that the ability of IDE to degrade Aβ decreases with Aβ aggregation and we identify Met 35 -Val 36 as a novel IDE cleavage site within the Aβ sequence (Chapter 5). As IDE-induced Aβ fragments are aggregation-prone, these findings must be considered in therapies that aim to increase Aβ clearance by upregulating the activity of proteases such as IDE.
Therapeutic strategies capable of interfering with Aβ-induced pathology in AD are the main focus of the third part of this thesis. The combination of docking analysis and molecular dynamics simulations allowed for the design of a series of new mimetic peptides possessing Aβ anti-aggregation properties (Chapter 6). Computer simulations provided mechanistic insights into their potential mode of action. We demonstrate that insertion of drug compounds in the core of an Aβ pentamer distorts Aβ structure by destabilizing several molecular interactions that play a key role in fibril formation. Moreover, we experimentally confirm the predicted inhibitory effect of these compounds on Aβ aggregation. Finally, as there is a shift in attention from single-target drugs to combination therapies that address the multifactorial nature of AD, we present a novel way of evaluating the complexity of Aβ in AD in chapter 7. We demonstrate that the dynamic Aβ network displays many similarities with an ecosystem and suggest that combining network medicine with general ecosystem management principles is a new and holistic approach to unravel AD mechanisms and potentially design more successful therapies.
To conclude, the research presented in this doctoral thesis illustrates the dynamic nature of Aβ and demonstrates that Aβ dynamics add an additional degree of complexity to the role of Aβ in AD. Fully understanding Aβ dynamics will most likely benefit the development of more effective AD therapies that can ultimately stop this devastating and widespread disease. 
